<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>EGb761, a standardized extract of Ginkgo biloba, has neuroprotective properties in animal models of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, an activity that is partially attributed to its constituent, bilobalide </plain></SENT>
<SENT sid="1" pm="."><plain>EGb761 has also been reported to inhibit <z:hpo ids='HP_0000969'>edema</z:hpo> formation induced by toxins such as triethyltin </plain></SENT>
<SENT sid="2" pm="."><plain>The goal of this study was to test the activity of pure bilobalide to prevent <z:hpo ids='HP_0000969'>edema</z:hpo> formation in models of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Oxygen-<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation (OGD) in rat hippocampal slices served as a model of in vitro-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>OGD caused cellular <z:hpo ids='HP_0000969'>edema</z:hpo> formation as indicated by an increase of slice water contents in 30 min </plain></SENT>
<SENT sid="5" pm="."><plain>Bilobalide (1-10 microM) reduced slice water contents in ischemic slices in a concentration-dependent manner </plain></SENT>
<SENT sid="6" pm="."><plain>As a model of in vivo-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, we performed middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) in mice </plain></SENT>
<SENT sid="7" pm="."><plain>Permanent MCAO caused cell <z:hpo ids='HP_0011420'>death</z:hpo> and swelling of the ischemic hemisphere within 24 h </plain></SENT>
<SENT sid="8" pm="."><plain>Pretreatment of the mice with bilobalide (10 mg/kg i.p.) reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> area by 43% (as judged by 2,3,5-triphenyl-tetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> (TTC) staining) and <z:hpo ids='HP_0000969'>edema</z:hpo> formation by 70% (as judged by hemispheric enlargement) </plain></SENT>
<SENT sid="9" pm="."><plain>In parallel experiments, pretreatment with bilobalide also reduced forebrain water contents in the ischemic hemisphere by 57% </plain></SENT>
<SENT sid="10" pm="."><plain>As an alternative model of <z:hpo ids='HP_0002181'>brain edema</z:hpo> formation, we used <z:e sem="disease" ids="C0043049" disease_type="Disease or Syndrome" abbrv="">water intoxication</z:e> to increase brain water content; bilobalide, was, however, inactive in this model </plain></SENT>
<SENT sid="11" pm="."><plain>We conclude that bilobalide strongly and specifically attenuates <z:hpo ids='HP_0000969'>edema</z:hpo> formation in models of <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> in vitro and in vivo </plain></SENT>
<SENT sid="12" pm="."><plain>Bilobalide may be therapeutically effective in <z:hpo ids='HP_0002181'>brain edema</z:hpo> which occurs secondarily to large hemispheric <z:hpo ids='HP_0001297'>stroke</z:hpo> and traumatic brain injury in humans </plain></SENT>
</text></document>